Angiotensin II administration was associated with a lower risk of 30-day mortality compared to conventional therapy alone in patients with shock (OR 0.74).
Cohort (n=811)
Yes
Does Angiotensin II reduce 30-day mortality in patients with shock receiving conventional vasopressor therapy?
In patients with shock, the addition of Angiotensin II to conventional vasopressors is associated with lower 30-day mortality, particularly in those receiving background norepinephrine equivalent doses between 0.4 and 0.6 mcg/kg/min.
Odds Ratio: 0.74 (95% CI 0.55–0.99)
Absolute Event Rate: 55.3% vs 56.9%
p-value: p=0.040
BACKGROUND: Angiotensin II (Ang II) is typically used in addition to adrenergic agents and vasopressin (conventional therapy) in patients with shock, but whether its use improves outcomes is unknown. RESEARCH QUESTION: We evaluated whether Ang II, when added to conventional therapy at different norepinephrine equivalent (NE) doses, was associated with mortality. METHODS: We performed a retrospective analysis of 811 patients admitted to four centers in a single healthcare system who received vasopressors for shock, including 275 who received Ang II plus conventional therapy and 536 who received only conventional therapy. Age, gender, sequential organ failure assessment score, serum lactate, background NE dose, corticosteroid use, pre-morbid angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and Charlson Comorbidity Index were calculated at initiation of Ang II or at an equivalent point of acuity in the conventional therapy cohort. We used propensity scores with inverse probability of treatment weighting (IPTW) to achieve covariate balance and multivariable logistic regression to compare 30-day mortality, further stratifying patients by 0.10 mcg/kg/min NE increments. RESULTS: Overall 30-day mortality was 56.4%. Groups statistically differed by all baseline variables. In multivariable logistic regression, Ang II treatment was associated with lower 30-day mortality compared to conventional therapy alone (odds ratio OR 0.65, 95% confidence interval CI 0.45-0.95, p = 0.025). After IPTW, Ang II use was independently associated with lower mortality (OR 0.74, 95% CI 0.55-0.99, p = 0.040). When stratifying by increments of background NE dose, Ang II initiation was associated with lower 30-day mortality compared to conventional therapy alone in patients on background NE doses > 0.4, > 0.5, and ≤ 0.6 mcg/kg/min. Ang II use in patients on background NE dose > 0.6 was not significantly associated with mortality. CONCLUSIONS: Ang II administration was associated with a lower risk of death in unadjusted and adjusted analyses. This effect was preserved only with patients receiving NE at doses ranging from 0.4 to 0.6 mcg/kg/min. Though additional prospective studies are required, these findings suggest that Ang II may be beneficial across a specific range of background vasopressor doses.
Busse et al. (Wed,) conducted a cohort in Shock (n=811). Angiotensin II plus conventional therapy vs. Conventional therapy alone was evaluated on 30-day mortality (OR 0.74, 95% CI 0.55-0.99, p=0.040). Angiotensin II administration was associated with a lower risk of 30-day mortality compared to conventional therapy alone in patients with shock (OR 0.74).